Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

MICHAEL E STEUER MD PC

NPI: 1922585629 · TUPELO, MS 38801 · Specialist · NPI assigned 07/25/2018

$266K
Total Medicaid Paid
13,630
Total Claims
10,992
Beneficiaries
10
Codes Billed
2018-09
First Month
2024-12
Last Month

Provider Details

Authorized OfficialSTEUER, MICHAEL (PRESIDENT/CEO)
NPI Enumeration Date07/25/2018

Related Entities

Other providers sharing the same authorized official: STEUER, MICHAEL

ProviderCityStateTotal Paid
MICHAEL E STEUER, MD, PC CORDOVA TN $2.63M
MIDSOUTH INTERVENTIONAL PAIN INSTITUTE, LLC GERMANTOWN TN $2.08M
MICHAEL E STEUER MD PC JACKSON TN $1.02M
MIDSOUTH INTERVENTIONAL PAIN INSTITUTE, LLC SOUTHAVEN MS $742K
MICHAEL E STEUER MD PC SOUTHAVEN MS $637K
MIDSOUTH INTERVENTIONAL PAIN INSTITUTE, LLC JACKSON TN $252K
MICHAEL E. STEUER MD PC OXFORD MS $234K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 42 $0.00
2019 1,631 $33K
2020 3,134 $71K
2021 3,492 $59K
2022 2,182 $45K
2023 1,237 $29K
2024 1,912 $29K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 3,192 2,385 $73K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 3,022 2,555 $65K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 2,952 2,437 $43K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 1,423 1,187 $38K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 644 542 $21K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 332 274 $14K
80305 1,540 1,247 $4K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 78 76 $4K
99203 Office or other outpatient visit for the evaluation and management of a new patient, low complexity 120 96 $3K
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) 327 193 $0.00